BridgeBio Pharma, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
BridgeBio Pharma, Inc. (BBIO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $11.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-10
- BridgeBio Pharma, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $1.17M.
- BridgeBio Pharma, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $10.41M, a 360.65% increase year-over-year.
- BridgeBio Pharma, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $2.85M, a 854.18% increase year-over-year.
- BridgeBio Pharma, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $1.46M.
- BridgeBio Pharma, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $6.57M, a 312.76% increase from fiscal 2024.
- BridgeBio Pharma, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $1.59M, a 34.94% increase from fiscal 2023.
- BridgeBio Pharma, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.18M, a 391.25% increase from fiscal 2022.
- BridgeBio Pharma, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $240.00K, a 96.24% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $11.58M 10-Q · filed 2026-08-10 | $14.43M derived: sum of 3 quarters · filed 2026-08-10 | $15.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $10.41M 10-Q · filed 2026-05-07 | $13.26M derived: sum of 2 quarters · filed 2026-05-07 | $14.71M derived: sum of 3 quarters · filed 2026-05-07 | $14.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.31M derived: sum of 2 quarters · filed 2026-02-24 | $4.31M derived: sum of 3 quarters · filed 2026-08-10 | $6.57M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.46M derived: sum of 2 quarters · filed 2026-08-10 | $3.71M 10-Q · filed 2025-10-29 | $4.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.26M 10-Q · filed 2026-08-10 | $2.56M derived: sum of 3 quarters · filed 2026-08-10 | $2.56M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.26M 10-Q · filed 2026-05-07 | $2.56M derived: sum of 2 quarters · filed 2026-05-07 | $2.56M derived: sum of 3 quarters · filed 2026-05-07 | $2.63M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $299.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $299.00K derived: sum of 2 quarters · filed 2026-02-24 | $367.00K derived: sum of 3 quarters · filed 2026-02-24 | $1.59M 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $68.00K derived: sum of 2 quarters · filed 2025-10-29 | $1.29M 10-Q · filed 2025-10-29 | $1.29M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $68.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.29M 10-Q · filed 2025-08-05 | $1.29M derived: sum of 3 quarters · filed 2026-02-24 | $1.64M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.22M 10-Q · filed 2025-04-29 | $1.22M derived: sum of 2 quarters · filed 2026-02-24 | $1.57M derived: sum of 3 quarters · filed 2026-02-24 | $1.57M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $351.00K derived: sum of 2 quarters · filed 2026-02-24 | $351.00K derived: sum of 3 quarters · filed 2026-02-24 | $1.18M 10-K · filed 2026-02-24 |
| 2023-09-30 | $351.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $351.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.18M 10-Q · filed 2024-11-12 | $1.18M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $828.00K 10-Q · filed 2024-08-01 | $828.00K derived: sum of 3 quarters · filed 2025-02-20 | $828.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $828.00K 10-Q · filed 2024-05-02 | $828.00K derived: sum of 2 quarters · filed 2025-02-20 | $828.00K derived: sum of 3 quarters · filed 2025-02-20 | $828.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $240.00K 10-K · filed 2025-02-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $240.00K 10-Q · filed 2023-11-02 | $240.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $240.00K 10-Q · filed 2023-08-03 | $240.00K derived: sum of 3 quarters · filed 2024-02-22 | $2.58M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $240.00K 10-Q · filed 2023-05-04 | $240.00K derived: sum of 2 quarters · filed 2024-02-22 | $2.58M derived: sum of 3 quarters · filed 2024-02-22 | $6.49M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.34M derived: sum of 2 quarters · filed 2024-02-22 | $6.25M derived: sum of 3 quarters · filed 2024-02-22 | $6.38M 10-K · filed 2024-02-22 |
| 2021-09-30 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.25M derived: sum of 2 quarters · filed 2022-11-03 | $6.38M 10-Q · filed 2022-11-03 | $14.16M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $3.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.04M 10-Q · filed 2022-08-04 | $11.82M derived: sum of 3 quarters · filed 2023-02-23 | $11.82M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $133.00K 10-Q · filed 2022-05-05 | $7.91M derived: sum of 2 quarters · filed 2023-02-23 | $7.91M derived: sum of 3 quarters · filed 2023-02-23 | $10.33M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $7.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $7.78M derived: sum of 2 quarters · filed 2023-02-23 | $10.20M derived: sum of 3 quarters · filed 2023-02-23 | $19.59M 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.42M derived: sum of 2 quarters · filed 2021-11-04 | $11.81M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $11.81M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $9.39M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |